Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anthera Pharmaceuticals IncANTH · Entity 163677 | Director | January 05, 2018 | January 09, 2018 |
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | EVP, Chief Financial Officer | March 17, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anthera Pharmaceuticals Inc
Report date January 05, 2018 · Filed January 09, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2028-01-05 | Direct | 84,705 |
Reported balance
After 2018-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-05 · Grant · Acquired 84,705 · Balance 84,705 F1: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2017. This option vests in 12 equal monthly installments. The vesting commencement date is April 27, 2017. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2028-01-05 | Direct | 84,705 |
Reported balance
After 2018-01-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-01-05 · Grant · Acquired 84,705 · Balance 84,705 F2: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2018. This option vests in 12 equal monthly installments. The vesting commencement date is commensurate with the grant date of January 5, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2017. This option vests in 12 equal monthly installments. The vesting commencement date is April 27, 2017.
F2: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2018. This option vests in 12 equal monthly installments. The vesting commencement date is commensurate with the grant date of January 5, 2018.
BIOMARIN PHARMACEUTICAL INC
Report date March 17, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,314 |
Reported balance
After 2026-03-17 transaction · row 1
1 source rowRow 1 · 2026-03-17 · Tax withholding · Disposed 2,117 · Balance 123,314 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2026 Filed Mar 19, 2026 20:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 2,117 | $56.05 | $118,657.85 |
DisclosureSEC source: 0001628280-26-019853 · wk-form4_1773953282.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,314 Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 00:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 44,600 | $0.00 Strike: $57.43 | $0.00 |
DisclosureSEC source: 0001628280-26-019008 · wk-form4_1773794751.xml · derivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,600 Underlying: Common Stock · 44,600 shares Expires 2036-03-15 F3 · derivative.exercise_date: Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 00:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 18,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-019008 · wk-form4_1773794751.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,431 F1 · price: Restricted stock units granted March 16, 2026. Price not applicable. F2 · balance_after: The Reporting Person's direct holdings have been adjusted by two shares to correct a previous clerical error. Read SEC document |
| March 13, 2026 Filed Mar 18, 2026 00:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 9,945 | $58.51 | $581,881.95 |
DisclosureSEC source: 0001628280-26-019008 · wk-form4_1773794751.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,691 Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 01:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 2,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-012529 · wk-form4_1772155735.xml · nonDerivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,638 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F5 · shares: Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 01:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 7,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-012529 · wk-form4_1772155735.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,069 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 01:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 6,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-012529 · wk-form4_1772155735.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,839 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| April 30, 2025 Filed Feb 14, 2026 00:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 375 | $54.14 | $20,301.38 |
DisclosureSEC source: 0001628280-26-008254 · wk-form5_1771027306.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,156 F1 · date: Represents the shares acquired by the reporting person on April 30, 2025, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 22:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 38,590 | $0.00 Strike: $71.55 | $0.00 |
DisclosureSEC source: 0001048477-25-000029 · wk-form4_1742336367.xml · derivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,590 Underlying: Common Stock · 38,590 shares Expires 2035-03-16 F2 · derivative.exercise_date: Option grant vests 12/48th on March 17, 2026 and 1/48th on the 17th day of each month thereafter. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 22:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 16,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000029 · wk-form4_1742336367.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,781 F1 · price: Restricted stock units granted March 17, 2025. Price not applicable. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 18,497 | $69.44 | $1,284,431.68 |
DisclosureSEC source: 0001048477-25-000029 · wk-form4_1742336367.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,141 Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 00:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000019 · wk-form4_1740701992.xml · nonDerivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,638 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F5 · shares: Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 00:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000019 · wk-form4_1740701992.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,271 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2025, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 00:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000019 · wk-form4_1740701992.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,611 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2025, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 20:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 588 | $82.33 | $48,410.04 |
DisclosureSEC source: 0001048477-24-000120 · wk-form4_1719865192.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,571 Read SEC document |
| May 30, 2024 Filed May 31, 2024 22:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 5,000 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001048477-24-000114 · wk-form4_1717194476.xml · derivative · entry 4 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 30, 2024 Filed May 31, 2024 22:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,000 | $75.19 | $375,950.00 |
DisclosureSEC source: 0001048477-24-000114 · wk-form4_1717194476.xml · nonDerivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,159 F2 · date: Trade made pursuant to a 10b5-1 plan executed on August 18, 2023. Read SEC document |
| May 30, 2024 Filed May 31, 2024 22:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 5,000 | $63.10 | $315,500.00 |
DisclosureSEC source: 0001048477-24-000114 · wk-form4_1717194476.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on August 18, 2023. Read SEC document |
| April 30, 2024 Filed May 31, 2024 22:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 300 | $68.65 | $20,593.80 |
DisclosureSEC source: 0001048477-24-000114 · wk-form4_1717194476.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,159 F1 · date: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 25,540 | $0.00 Strike: $83.87 | $0.00 |
DisclosureSEC source: 0001048477-24-000044 · wk-form4_1710895692.xml · derivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,540 Underlying: Common Stock · 25,540 shares Expires 2034-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2025 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 20,789 | $83.87 | $1,743,573.43 |
DisclosureSEC source: 0001048477-24-000044 · wk-form4_1710895692.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,859 Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000044 · wk-form4_1710895692.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,648 F1 · price: Restricted stock units granted March 15, 2024. Price not applicable. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:18 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 6,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000028 · wk-form4_1709245123.xml · nonDerivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,248 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F5 · shares: Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:18 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 8,802 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000028 · wk-form4_1709245123.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,145 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:18 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 20,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000028 · wk-form4_1709245123.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,343 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 15:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 576 | $88.93 | $51,223.68 |
DisclosureSEC source: 0001048477-23-000023 · wk-form4_1688139350.xml · nonDerivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,805 Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 15:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 4,602 | $88.93 | $409,255.86 |
DisclosureSEC source: 0001048477-23-000023 · wk-form4_1688139350.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,381 Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 15:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 4,602 | $88.93 | $409,255.86 |
DisclosureSEC source: 0001048477-23-000023 · wk-form4_1688139350.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,983 Read SEC document |
| April 28, 2023 Filed Feb 12, 2024 20:04 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 318 | $66.88 | $21,267.20 |
DisclosureSEC source: 0001048477-24-000006 · wk-form5_1707768227.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,123 F1 · date: Represents the shares acquired by the reporting person on April 28, 2023, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 16, 2023 Filed Mar 18, 2023 01:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,973 | $93.41 | $371,117.93 |
DisclosureSEC source: 0001567619-23-005297 · doc1.xml · nonDerivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,585 Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 21,970 | $0.00 Strike: $87.74 | $0.00 |
DisclosureSEC source: 0001567619-23-005297 · doc1.xml · derivative · entry 4 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,970 Underlying: Common Stock · 21,970 shares Expires 2033-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2024 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 2,708 | $87.74 | $237,599.92 |
DisclosureSEC source: 0001567619-23-005297 · doc1.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,558 Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-005297 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,266 F1 · price: Restricted stock units granted on March 15, 2023. Price not applicable. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014617 · doc4.xml · nonDerivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,636 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: approximately 20% vests on March 16, 2023 and approximately 80% vests on June 29, 2023, subject to the reporting person's continued service through such dates, subject to earlier vesting upon certain events. F5 · shares: Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 10,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014617 · doc4.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,386 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: approximately 20% vests on March 16, 2023 and approximately 80% vests on June 29, 2023, subject to the reporting person's continued service through such dates, subject to earlier vesting upon certain events. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014617 · doc4.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,406 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: approximately 20% vests on March 16, 2023 and approximately 80% vests on June 29, 2023, subject to the reporting person's continued service through such dates, subject to earlier vesting upon certain events. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 02:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 2,500 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001567619-23-000965 · doc1.xml · derivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 02:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,500 | $114.50 | $286,250.00 |
DisclosureSEC source: 0001567619-23-000965 · doc1.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,746 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 02:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 2,500 | $63.10 | $157,750.00 |
DisclosureSEC source: 0001567619-23-000965 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 23:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 2,500 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001567619-22-021667 · doc1.xml · derivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 23:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,500 | $107.50 | $268,750.00 |
DisclosureSEC source: 0001567619-22-021667 · doc1.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,746 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 23:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 2,500 | $63.10 | $157,750.00 |
DisclosureSEC source: 0001567619-22-021667 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| December 02, 2022 Filed Dec 7, 2022 02:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 3,761 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-22-021363 · doc1.xml · derivative · entry 7 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,761 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| December 02, 2022 Filed Dec 7, 2022 02:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 2,139 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-22-021363 · doc1.xml · derivative · entry 6 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,139 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| December 02, 2022 Filed Dec 7, 2022 02:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,761 | $104.50 | $393,024.50 |
DisclosureSEC source: 0001567619-22-021363 · doc1.xml · nonDerivative · entry 5 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,746 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| December 02, 2022 Filed Dec 7, 2022 02:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,761 | $67.81 | $255,033.41 |
DisclosureSEC source: 0001567619-22-021363 · doc1.xml · nonDerivative · entry 4 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| December 02, 2022 Filed Dec 7, 2022 02:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,139 | $104.50 | $223,525.50 |
DisclosureSEC source: 0001567619-22-021363 · doc1.xml · nonDerivative · entry 3 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,746 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| December 02, 2022 Filed Dec 7, 2022 02:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 2,139 | $67.81 | $145,045.59 |
DisclosureSEC source: 0001567619-22-021363 · doc1.xml · nonDerivative · entry 2 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| December 02, 2022 Filed Dec 7, 2022 02:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,101 | $104.50 | $115,054.50 |
DisclosureSEC source: 0001567619-22-021363 · doc1.xml · nonDerivative · entry 1 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,746 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. Read SEC document |
| November 23, 2022 Filed Nov 29, 2022 02:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 3,500 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-22-020937 · doc1.xml · derivative · entry 5 Mueller Brian · CIK 0001514980 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,761 Underlying: Common Stock · 3,500 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 14, 2022. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.